{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:39:09Z","timestamp":1792701549830,"version":"4.5.0"},"reference-count":60,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"crossref","award":["20250204037YY"],"award-info":[{"award-number":["20250204037YY"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Rabies is an acute and fatal zoonotic disease caused by the rabies virus, responsible for approximately 59,000 deaths worldwide each year. Once clinical symptoms manifest, the case fatality rate approaches 100%. Vaccination remains the only effective strategy for prevention and control. Currently, human rabies vaccines approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA), and the China National Medical Products Administration (NMPA) are all inactivated, adjuvant-free formulations. These vaccines are associated with several limitations, including weak immunogenicity, delayed induction of neutralizing antibodies, complex immunization schedules, and poor patient compliance. Adjuvants, as nonspecific immunoenhancers, can potentiate the immune response even at low antigen doses and reduce the number of required doses, offering a promising approach to overcome the aforementioned challenges. This article reviews recent advances in adjuvants suitable for rabies vaccines and discusses the key challenges currently faced in the development of adjuvanted rabies vaccines.<\/jats:p>","DOI":"10.3390\/vaccines14020132","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:04:46Z","timestamp":1769612686000},"page":"132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Adjuvanted Rabies Vaccines"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9584-9755","authenticated-orcid":false,"given":"Yutian","family":"Wang","sequence":"first","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd., Changchun 130012, China"},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Co., Ltd., Beijing 100024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Sun","sequence":"additional","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd., Changchun 130012, China"},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Co., Ltd., Beijing 100024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Wu","sequence":"additional","affiliation":[{"name":"Changchun Institute of Biological Products Co., Ltd., Changchun 130012, China"},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Co., Ltd., Beijing 100024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref_1","unstructured":"Klein, R.S., and Levin, M.C. (2025, December 20). Rabies. In MSD Manual Professional Edition. Available online: https:\/\/www.msdmanuals.com\/professional\/neurologic-disorders\/brain-infections\/rabies."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1473-3099(24)00506-1","article-title":"Heading in the direction of ending human deaths from dog-mediated rabies","volume":"25","author":"Schneider","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tidman, R., Thumbi, S.M., Wallace, R., De Balogh, K., Iwar, V., Dieuzy-Labaye, I., Song, J., Shadomy, S., Qiu, Y., and Torres, G. (2022). United Against Rabies Forum: The One Health Concept at Work. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.854419"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100490","DOI":"10.1016\/j.ijregi.2024.100490","article-title":"Combatting rabies outbreaks in Vietnam: High time to enforce restrictions on dog meat farming, a key source of transmission","volume":"13","author":"Quan","year":"2024","journal-title":"IJID Reg."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sing, A. (2023). Elimination of Rabies: A Missed Opportunity. Zoonoses: Infections Affecting Humans and Animals, Springer.","DOI":"10.1007\/978-3-031-27164-9"},{"key":"ref_6","first-page":"1363","article-title":"Rabies in Europe: An epidemiological and clinical update","volume":"40","author":"Riccardi","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.prevetmed.2016.07.015","article-title":"Rabies disease dynamics in na\u00efve dog populations in Australia","volume":"131","author":"Sparkes","year":"2016","journal-title":"Prev. Vet. Med."},{"key":"ref_8","unstructured":"World Health Organization (2018). Rabies vaccines: WHO position paper. Wkly. Epidemiol. Rec., 93, 309\u2013320."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/QCO.0000000000000420","article-title":"Rabies: Changing prophylaxis and new insights in pathophysiology","volume":"31","author":"Ugolini","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gluska, S., Zahavi, E.E., Chein, M., Gradus, T., Bauer, A., Finke, S., and Perlson, E. (2014). Rabies Virus Hijacks and accelerates the p75NTR retrograde axonal transport machinery. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004348"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/QCO.0000000000000578","article-title":"WHO\u2019s new rabies recommendations: Implications for high incidence countries","volume":"32","author":"Pattanaik","year":"2019","journal-title":"Curr. Opin. Infect. Diseases"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.20517\/ohir.2022.46","article-title":"WHO\u2019s latest rabies recommendations and guidance save lives and reduce the cost of treatment","volume":"3","author":"Bote","year":"2023","journal-title":"One Health Implement. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, H., Wang, S., Fang, R., Li, X., Xing, J., Li, Z., and Song, N. (2023). Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies. Vaccines, 12.","DOI":"10.3390\/vaccines12010038"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention (2023). Human Rabies Prevention\u2014United States, 2023 Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep., 72, 1\u201328.","DOI":"10.15585\/mmwr.rr7205a1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1080\/21645515.2018.1549450","article-title":"Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: A randomized clinical trial","volume":"15","author":"Zhou","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_16","unstructured":"National Disease Control and Prevention Administration & National Health Commission of the People\u2019s Republic of China (2025, December 20). Guidelines for the Management of Rabies Exposure Prophylaxis and Treatment (2023 Version), Available online: https:\/\/cdcp.gd.gov.cn\/zwgk\/zcfg\/flfg\/content\/post_4254940.html."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.carres.2007.01.012","article-title":"Monophosphoryl lipid A analogues with varying 3-O-substitution: Synthesis and potent adjuvant activity","volume":"342","author":"Jiang","year":"2007","journal-title":"Carbohydr. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wang, Y.Q., Bazin-Lee, H., Evans, J.T., Casella, C.R., and Mitchell, T.C. (2020). MPL Adjuvant Contains Competitive Antagonists of Human TLR4. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.577823"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chen, C., Zhang, C., Li, R., Wang, Z., Yuan, Y., Li, H., Fu, Z., Zhou, M., and Zhao, L. (2019). Monophosphoryl-Lipid A (MPLA) is an Efficacious Adjuvant for Inactivated Rabies Vaccines. Viruses, 11.","DOI":"10.3390\/v11121118"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.imbio.2013.05.006","article-title":"Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB\/c mice","volume":"218","author":"Hu","year":"2013","journal-title":"Immunobiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/jleuko\/qiad030","article-title":"Enhanced TLR5-dependent migration and activation of antigen-loaded airway dendritic cells by flagellin","volume":"113","author":"Li","year":"2023","journal-title":"J. Leukoc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00705-015-2704-8","article-title":"Immunoenhancement with flagellin as an adjuvant to whole-killed rabies vaccine in mice","volume":"161","author":"Xiao","year":"2016","journal-title":"Arch. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","article-title":"CpG Oligonucleotides as Vaccine Adjuvants","volume":"2197","author":"Kayraklioglu","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12985-018-1089-1","article-title":"A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice","volume":"15","author":"Yu","year":"2018","journal-title":"Virol. J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chasaide, C.N., and Mills, K.H.G. (2020). Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract. Vaccines, 8.","DOI":"10.3390\/vaccines8040621"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1016\/j.vaccine.2023.10.001","article-title":"Potential option for rabies post-exposure prophylaxis: New vaccine with PIKA adjuvant against diverse Chinese rabies strains","volume":"41","author":"Yu","year":"2023","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.vaccine.2008.12.048","article-title":"A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic","volume":"27","author":"Lau","year":"2009","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2015.10.029","article-title":"A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies","volume":"489","author":"Zhang","year":"2016","journal-title":"Virology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1016\/j.vaccine.2017.10.097","article-title":"A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen","volume":"35","author":"Kalimuddin","year":"2017","journal-title":"Vaccine"},{"key":"ref_30","unstructured":"Yisheng Biopharma (Singapore) Pte. Ltd (2025, December 20). A Phase III Study to Evaluate the Immunogenicity, Safety and Lot to Lot Consistency of Three Lots of a PIKA Rabies Vaccine (Vero cell) for Human Use, Freeze-Dried in Healthy Adults Using a Post-exposure Prophylaxis Schedule (NCT05667974), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05667974."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gao, G., He, C., Wang, H., Guo, J., Ke, L., Zhou, J., Chong, P.H., and Rao, P. (2021). Polysaccharide Nanoparticles from Isatis indigotica Fort. Root Decoction: Diversity, Cytotoxicity, and Antiviral Activity. Nanomaterials, 12.","DOI":"10.3390\/nano12010030"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijbiomac.2016.02.023","article-title":"Isatis indigotica root polysaccharides as adjuvants for an inactivated rabies virus vaccine","volume":"87","author":"Zhang","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12250-021-00349-z","article-title":"Artesunate and Dihydroartemisinin Inhibit Rabies Virus Replication","volume":"36","author":"Luo","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1016\/j.vaccine.2019.09.077","article-title":"Artesunate enhances the immune response of rabies vaccine as an adjuvant","volume":"37","author":"Luo","year":"2019","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41589-023-01538-5","article-title":"Complete biosynthesis of QS-21 in engineered yeast","volume":"20","author":"Martin","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00044-024-03227-x","article-title":"Development of semisynthetic saponin immunostimulants","volume":"33","author":"Bai","year":"2024","journal-title":"Med. Chem. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s44321-024-00076-4","article-title":"A broadly applicable protein-polymer adjuvant system for antiviral vaccines","volume":"16","author":"Wang","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.vaccine.2016.03.070","article-title":"A rabies vaccine adjuvanted with saponins from leaves of the soap tree (Quillaja brasiliensis) induces specific immune responses and protects against lethal challenge","volume":"34","author":"Yendo","year":"2016","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.intimp.2014.03.008","article-title":"Ginsenoside Re as an adjuvant to enhance the immune response to the inactivated rabies virus vaccine in mice","volume":"20","author":"Su","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2174\/1871520611313050002","article-title":"The use of lentinan for treating gastric cancer","volume":"13","author":"Ina","year":"2013","journal-title":"Anticancer. Agents Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"128118","DOI":"10.1016\/j.ijbiomac.2023.128118","article-title":"Single-injection subunit vaccine for rabies prevention using lentinan as adjuvant","volume":"254","author":"Zhou","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1186\/s12951-024-02993-5","article-title":"IL-7 promotes mRNA vaccine-induced long-term immunity","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41541-025-01098-w","article-title":"Optimizing rabies mRNA vaccine efficacy via RABV-G structural domain screening and heterologous prime-boost immunization","volume":"10","author":"Li","year":"2025","journal-title":"NPJ Vaccines"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12985-022-01919-7","article-title":"An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs","volume":"19","author":"Li","year":"2022","journal-title":"Virol. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ymthe.2024.12.041","article-title":"A nucleoside-modified rabies mRNA vaccine induces long-lasting and comprehensive immune responses in mice and non-human primates","volume":"33","author":"Wang","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Pardi, N., and Krammer, F. (Nat. Rev. Drug Discov., 2024). mRNA vaccines for infectious diseases\u2014Advances, challenges and opportunities, Nat. Rev. Drug Discov., advanced online publication.","DOI":"10.1038\/s41573-024-01042-y"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"ref_48","first-page":"1","article-title":"Liposomes as Adjuvants and Vaccine Delivery Systems","volume":"16","author":"Tretiakova","year":"2022","journal-title":"Biochem. (Mosc) Suppl. Ser. A Membr. Cell Biol."},{"key":"ref_49","first-page":"810","article-title":"Immunization Schedule of Liposomal Rabies Vaccine in Animals","volume":"26","author":"Guo","year":"2010","journal-title":"Chem. Res. Chin. Univ."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2018.1531966","article-title":"Application of a novel nanoemulsion adjuvant for rabies vaccine which stabilizes a Krebs cycle intermediate (SDH) in an animal model","volume":"15","author":"Ze","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cao, H., Li, H., Liu, W., Luan, N., Hu, J., Kong, M., Song, J., and Liu, C. (2025). A QS21+CpG-Adjuvanted Rabies Virus G Subunit Vaccine Elicits Superior Humoral and Moderate Cellular Immunity. Vaccines, 13.","DOI":"10.3390\/vaccines13080887"},{"key":"ref_52","unstructured":"World Health Organization (2013). WHO Expert Committee on Biological Standardization: Sixty-Fourth Report, World Health Organization."},{"key":"ref_53","unstructured":"World Health Organization (2024). Conditions for acceptance of an application. WHO Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control), World Health Organization."},{"key":"ref_54","unstructured":"Abela-Ridder, B. (2024, January 25\u201326). Technical update on WHO\u2019s position on rabies vaccines and post-exposure prophylaxis. Proceedings of the GAVI Human Rabies Vaccine Application Workshop, Cape Town, South Africa."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41586-024-07345-9","article-title":"Complete biosynthesis of QS-21 in engineered yeast","volume":"629","author":"Liu","year":"2024","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13068-022-02208-9","article-title":"Metabolic recycling of storage lipids promotes squalene biosynthesis in yeast","volume":"15","author":"Son","year":"2022","journal-title":"Biotechnol. Biofuels Bioprod."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s43856-025-01147-4","article-title":"Durability of next-generation self-replicating RNA vaccine RBI-4000: A phase 1, randomized open label clinical trial","volume":"5","author":"Maine","year":"2025","journal-title":"Commun. Med."},{"key":"ref_58","unstructured":"World Health Organization (2024). WHO position paper on rabies vaccines and immunoglobulins\u2013October 2024. Wkly. Epidemiol. Rec., 99, 561\u2013580."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100375","DOI":"10.1016\/j.lansea.2024.100375","article-title":"Zero by 30 and microarray patches","volume":"23","author":"Dodman","year":"2024","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4068\/cmj.2025.61.2.84","article-title":"Oxidized Mannan: A Novel Adjuvant Candidate for Enhancing Immune Responses in Veterinary Rabies Vaccine","volume":"61","author":"Mardani","year":"2025","journal-title":"Chonnam Med. J."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/2\/132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:16:21Z","timestamp":1769750181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/2\/132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["vaccines14020132"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14020132","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}